Navigation Links
Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Date:4/9/2013

BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with Genentech/Novartis's Xolair, the only approved drug that serves this population. However, by the end of 2018, when three novel biologics and biosimilar versions of Xolair are expected to be available, surveyed pulmonologists estimate that nearly 50 percent of their severe, refractory patients will be treated. This response demonstrates the great unmet need for this population that will be at least partially filled by the emerging biologics.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The new U.S. Physician & Payer Forum report entitled How Will U.S. Physician and Payer Attitudes and Decisions Shape the Asthma Market for Patients with Severe, Refractory Disease? also finds that most surveyed pulmonologists are receptive to prescribing biosimilar versions of Xolair in their first year of availability and intend to prescribe Boehringer Ingelheim/Pfizer's Spiriva upon its approval for asthma. As a result, these prescribing habits could delay prescribing of branded biologics to a later line of therapy.

The report also finds that surveyed managed care organization (MCO) pharmacy and medical directors' expected formulary tier positions of emerging biologics depend on price more so than potential Phase III clinical trial results, suggesting that price point is important for ensuring favorable formulary coverage despite the unmet need for additional treatment options for severe, refractory asthma.

"Surveyed payers indicated that the most common restriction placed on the emerging biologics will be prior authorization, which is similar to what is currently in place for Xolair," said Decision Resources Analyst Colleen Albacker , Ph.D. "Forty-one percent of patients eligible for Xolair never receive the drug, with pulmonologists citing cost- and reimbursement-related issues as the major reasons, and the emerging biologics may face the same fate due to payer cost controls."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
7. ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements
8. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
9. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
10. Asthma and COPD Drug Market Expected to Reach USD 26,965.5 Million Globally in 2017: Transparency Market Research
11. Medical Alarm Lands European Order with Additional Orders Expected
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
Breaking Medicine News(10 mins):